TherapeuticsMD (TXMD) Misses Q4 EPS by 1c

TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.66 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Birkenstock Holding (BIRK) Misses Q3 EPS by 2c; lifts guidance
• FGI Industries Ltd (FGI) Tops Q2 EPS by 59c
• Gaxos.ai Inc. (GXAI) Reports Q2 EPS of $0.02